Despite the multiple beneficial therapeutic effects of SGLT2 inhibitors, fresh concerns have emerged regarding their potential to elevate the risk of euglycemic diabetic ketoacidosis (euDKA), particularly in individuals with type 1 diabetes mellitus (T1DM) and latent autoimmune diabetes (LADA) [8,9]. The gene discussed is SLC5A2; the disease is diabetes mellitus.